Pharma Mar, S.A. (PHMMF)
- Previous Close
26.85 - Open
26.85 - Bid --
- Ask --
- Day's Range
26.85 - 26.85 - 52 Week Range
26.85 - 46.26 - Volume
54 - Avg. Volume
67 - Market Cap (intraday)
497.23M - Beta (5Y Monthly) -0.08
- PE Ratio (TTM)
447.50 - EPS (TTM)
0.06 - Earnings Date --
- Forward Dividend & Yield 0.70 (2.61%)
- Ex-Dividend Date Jun 7, 2023
- 1y Target Est
--
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
www.pharmamar.comRelated News
Performance Overview: PHMMF
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHMMF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHMMF
Valuation Measures
Market Cap
497.23M
Enterprise Value
370.38M
Trailing P/E
421.35
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.86
Price/Book (mrq)
2.29
Enterprise Value/Revenue
2.34
Enterprise Value/EBITDA
81.42
Financial Highlights
Profitability and Income Statement
Profit Margin
0.72%
Return on Assets (ttm)
-0.65%
Return on Equity (ttm)
0.55%
Revenue (ttm)
158.15M
Net Income Avi to Common (ttm)
1.14M
Diluted EPS (ttm)
0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
162.56M
Total Debt/Equity (mrq)
22.58%
Levered Free Cash Flow (ttm)
-12.59M